Impact of PARP Inhibitors on Health-related Quality of Life in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis

Take Home Message We found no statistically or clinically meaningful deterioration in health-related quality of life (HRQoL) with PARP inhibitor (PARPi) in patients with metastatic castration-resistant prostate cancer (mCRPC), and one study suggested a potential benefit. These findings support the favourable balance between the efficacy and tolerability of PARPi treatment in mCRPC management, although current HRQoL assessment tools may underestimate subtle but clinically relevant patient experiences in the palliative setting.

• Publication year

  2025

• Venue

  European Urology Open Science

• Publication date

  2025-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.euros.2025.08.008PMID 40994543PMCID 12454867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.

  2025cited by this paper
• 2025 ANZUP Annual Scientific Meeting, 20-22 July 2025. Hyatt Regency Sydney.

  2025cited by this paper
• Toxicities of PARP inhibitors in genitourinary cancers

  2025cited by this paper
• Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial.

  2025cited by this paper
• First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

  2025influential reference
• Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.

  2024cited by this paper
• Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial.

  2024cited by this paper
• Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial.

  2024cited by this paper
• EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

  2024cited by this paper
• Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis

  2024cited by this paper
• Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.

  2023cited by this paper
• Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

  2023cited by this paper
• Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

  2023cited by this paper
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

  2023influential reference
• Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

  2023cited by this paper
• Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

  2022cited by this paper
• Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis

  2022cited by this paper
• A Systematic Review to Evaluate Patient-Reported Outcome Measures (PROMs) for Metastatic Prostate Cancer According to the COnsensus-Based Standard for the Selection of Health Measurement INstruments (COSMIN) Methodology

  2022cited by this paper
• Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey

  2022cited by this paper
• Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.

  2022influential reference
• Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.

  2022influential reference
• Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.

  2022influential reference
• Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2022cited by this paper
• Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors

  2021cited by this paper
• [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

  2021cited by this paper
• Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

  2021cited by this paper
• Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• Characterization of Models for Identifying Physical and Cognitive Frailty in Older Adults With Diabetes: Systematic Review and Meta-Analysis

  2020cited by this paper
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• Brief Pain Inventory-Short Form: A New Method for Assessing Pain in the Emergency Department.

  2020cited by this paper
• Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.

  2020cited by this paper
• PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

  2019cited by this paper
• RoB 2: a revised tool for assessing risk of bias in randomised trials

  2019cited by this paper
• Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

  2019cited by this paper
• Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2018cited by this paper
• Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews

  2018cited by this paper
• Intercoder Reliability and Validity of WebPlotDigitizer in Extracting Graphed Data

  2017influential reference
• Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings

  2017cited by this paper
• AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

  2017cited by this paper
• BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer

  2017cited by this paper
• The internal and external responsiveness of Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Short Form-12 Health Survey version 2 (SF-12 v2) in patients with prostate cancer

  2016cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016influential reference
• Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.

  2016cited by this paper
• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

  2015cited by this paper
• Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279)

  2015cited by this paper
• Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

  2011cited by this paper
• Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT‐P Symptom Index

  2011cited by this paper
• Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.

  2009cited by this paper
• Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

  1997cited by this paper

• Polydopamine-Coated Surfaces Promote Adhesion, Migration, Proliferation, Chemoresistance, Stemness, and Epithelial–Mesenchymal Transition of Human Prostate Cancer Cell Lines In Vitro via Integrin α2β1–FAK–JNK Signaling

  2026cites this paper